4.6 Article

Ineffective CD8+ T-Cell Immunity to Adeno-Associated Virus Can Result in Prolonged Liver Injury and Fibrogenesis

Journal

AMERICAN JOURNAL OF PATHOLOGY
Volume 179, Issue 5, Pages 2370-2381

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajpath.2011.08.004

Keywords

-

Categories

Funding

  1. NIH [DK075274]

Ask authors/readers for more resources

Chronic viral hepatitis depends on the inability of the T-cell immune response to eradicate antigen. This results in a sustained immune response accompanied by tissue injury and fibrogenesis. We have created a mouse model that reproduces these effects, based on the response of CD8(+) T cells to hepatocellular antigen delivered by an adeno-associated virus (AAV) vector. Ten thousand antigen-specific CD8(+) T cells undergo slow expansion in the liver and can precipitate a subacute inflammatory hepatitis with stellate cell activation and fibrosis. Over time, antigen-specific CD8(+) T cells show signs of exhaustion, including high expression of PD-1, and eventually both inflammation and fibrosis resolve. This model allows the investigation of both chronic liver immunopathology and its resolution. (Am J Pathol 2011, 179:2370-2381; DOI: 10.1016/j.ajpath.2011.08.004)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Amita Patnaik, S. Peter Kang, Drew Rasco, Kyriakos P. Papadopoulos, Jeroen Elassaiss-Schaap, Muralidhar Beeram, Ronald Drengler, Cong Chen, Lon Smith, Guillermo Espino, Kevin Gergich, Liliana Delgado, Adil Daud, Jill A. Lindia, Xiaoyun Nicole Li, Robert H. Pierce, Jennifer H. Yearley, Dianna Wu, Omar Laterza, Manfred Lehnert, Robert Iannone, Anthony W. Tolcher

CLINICAL CANCER RESEARCH (2015)

Article Biotechnology & Applied Microbiology

In-situ tumor vaccination: Bringing the fight to the tumor

Robert H. Pierce, Jean S. Campbell, Sara I. Pai, Joshua D. Brody, Holbrook E. K. Kohrt

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)

Article Biochemistry & Molecular Biology

Improving therapeutic efficacy of IL-12 intratumoral gene electrotransfer through novel plasmid design and modified parameters

C. Burkart, A. Mukhopadhyay, S. A. Shirley, R. J. Connolly, J. H. Wright, A. Bahrami, J. S. Campbell, R. H. Pierce, D. A. Canton

GENE THERAPY (2018)

Article Immunology

Interleukin-23 is sufficient to induce rapid de novo legut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells

I. H. Chan, R. Jain, M. S. Tessmer, D. Gorman, R. Mangadu, M. Sathe, F. Vives, C. Moon, E. Penaflor, S. Turner, G. Ayanoglu, C. Chang, B. Basham, J. B. Mumm, R. H. Pierce, J. H. Yearley, T. K. McClanahan, J. H. Phillips, D. J. Cua, E. P. Bowman, R. A. Kastelein, D. LaFace

MUCOSAL IMMUNOLOGY (2014)

Article Multidisciplinary Sciences

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley, I. Peter Shintaku, Emma J. M. Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu, Alisha N. West, Manuel Carmona, Christine Kivork, Elizabeth Seja, Grace Cherry, Antonio J. Gutierrez, Tristan R. Grogan, Christine Mateus, Gorana Tomasic, John A. Glaspy, Ryan O. Emerson, Harlan Robins, Robert H. Pierce, David A. Elashoff, Caroline Robert, Antoni Ribas

NATURE (2014)

Editorial Material Immunology

Killer T cells find meaningful encounters through iMATEs

Ian N. Crispe, Robert H. Pierce

NATURE IMMUNOLOGY (2013)

Article Biochemistry & Molecular Biology

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells

Jonathan P. Sherlock, Barbara Joyce-Shaikh, Scott P. Turner, Cheng-Chi Chao, Manjiri Sathe, Jeff Grein, Daniel M. Gorman, Edward P. Bowman, Terrill K. McClanahan, Jennifer H. Yearley, Gerard Eberl, Christopher D. Buckley, Robert A. Kastelein, Robert H. Pierce, Drake M. LaFace, Daniel J. Cua

NATURE MEDICINE (2012)

Article Biochemistry & Molecular Biology

Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy

Anandaroop Mukhopadhyay, Jocelyn Wright, Shawna Shirley, David A. Canton, Christoph Burkart, Richard J. Connolly, Jean S. Campbell, Robert H. Pierce

GENE THERAPY (2019)

Article Oncology

Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma

Ingunn M. Stromnes, Adam L. Burrack, Ayaka Hulbert, Patrick Bonson, Cheryl Black, J. Scott Brockenbrough, Jackson F. Raynor, Ellen J. Spartz, Robert H. Pierce, Philip D. Greenberg, Sunil R. Hingorani

CANCER IMMUNOLOGY RESEARCH (2019)

Article Oncology

Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses

Samantha K. Greaney, Alain P. Algazi, Katy K. Tsai, Kathryn T. Takamura, Lawrence Chen, Christopher G. Twitty, Li Zhang, Alan Paciorek, Robert H. Pierce, Mai H. Le, Adil Daud, Lawrence Fong

CANCER IMMUNOLOGY RESEARCH (2020)

Review Oncology

The Liver-Immunity Nexus and Cancer Immunotherapy

James C. Lee, Michael D. Green, Laura A. Huppert, Christine Chow, Robert H. Pierce, Adil Daud

Summary: Liver metastases have a significant impact on the effectiveness of immune checkpoint inhibitors in patients with solid-tumor malignancies. Multiple clinical and translational studies have shown that liver metastasis leads to systemic immune suppression through the generation of suppressive macrophages and activation of regulatory T-cells. Various interventions, such as radiation therapy and combination checkpoint blockade, have been reported to address liver immune suppression.

CLINICAL CANCER RESEARCH (2022)

Article Oncology

Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells

Peter H. Goff, Laura Riolobos, Bonnie J. LaFleur, Matthew B. Spraker, Y. David Seo, Kimberly S. Smythe, Jean S. Campbell, Robert H. Pierce, Yuzheng Zhang, Qianchuan He, Edward Y. Kim, Stephanie K. Schaub, Gabrielle M. Kane, Jose G. Mantilla, Eleanor Y. Chen, Robert Ricciotti, Matthew J. Thompson, Lee D. Cranmer, Michael J. Wagner, Elizabeth T. Loggers, Robin L. Jones, Erin Murphy, Wendy M. Blumenschein, Terrill K. McClanahan, Jon Earls, Kevin C. Flanagan, Natalie A. LaFranzo, Teresa S. Kim, Seth M. Pollack

Summary: This study aims to characterize the changes in the soft-tissue sarcoma (STS) tumor immune microenvironment induced by standard neoadjuvant therapy and provides insights for neoadjuvant immunotherapy trial design. The results show that neoadjuvant therapy significantly increases immune cell infiltration in the tumor and affects the expression of immune-related genes and cytokines. These findings inform the incorporation of immune checkpoint inhibitors and novel immunotherapies into the neoadjuvant setting for STSs.

CLINICAL CANCER RESEARCH (2022)

Article Oncology

Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma

Robert H. I. Andtbacka, Yan Wang, Robert H. Pierce, Jean S. Campbell, Melinda Yushak, Mohammed Milhem, Merrick Ross, Katie Niland, Robert D. Arbeit, Sudha Parasuraman, Kris Bickley, Cecilia C. S. Yeung, Lauri D. Aicher, Kimberly S. Smythe, Lu Gan

Summary: The study found that treatment with single-agent mavorixafor can increase CD8+ T-cell infiltration, granzyme B signal, antigen presentation machinery, and both tumor inflammatory signature (TIS) and IFNγ gene expression signature scores. When mavorixafor was combined with pembrolizumab, the increases in the key serum cytokines CXCL9 and CXCL10 were further enhanced. Reported adverse events included diarrhea, fatigue, maculopapular rash, and dry eye, all of which were ≤ grade 3.

CANCER RESEARCH COMMUNICATIONS (2022)

Meeting Abstract Oncology

Systemic antitumor effect and clinical response in a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma.

Adil Daud, Alain Patrick Algazi, Michelle T. Ashworth, Lawrence Fong, Jera Lewis, Stephen E. Chan, Michael Buljan, Manuel Alberto Molina, Kathryn Toshimi Takamura, Tuan Tu Diep, Richard Heller, Robert H. Pierce, Shailender Bhatia

JOURNAL OF CLINICAL ONCOLOGY (2014)

Meeting Abstract Medicine, General & Internal

Interleukin 23 is critical in the pathogenesis of spondyloarthropathy and acts on a novel population of interleukin 23R+entheseal resident cells

Jonathan P. Sherlock, Barbara Joyce-Shaikh, Scott Turner, Manjiri Sathe, Jeff Grein, Daniel M. Gorman, Edward P. Bowman, Terrill K. McClanahan, Jennifer Yearley, Christopher D. Buckley, Robert A. Kastelein, Robert H. Pierce, Drake LaFace, Daniel J. Cua

LANCET (2013)

No Data Available